22 Mar Impel NeuroPharma Expands Patent Portfolio
The U.S. Patent and Trademark Office (USPTO) has issued to Impel NeuroPharma, Inc. a patent relating to the company’s POD™ device. Patent number 9,550,036, entitled “NASAL DRUG DELIVERY DEVICE,” is directed to a device for delivery of compounds to the nasal cavity and methods of using the same. Impel is currently developing treatments for migraine, Alzheimer’s disease and Parkinson’s disease that are intranasally delivered.
“This is an important addition to our growing portfolio of issued patents covering our POD™ device,” stated Dr. John Hoekman, Interim CEO and Founder of Impel. “Our POD™ device is being utilized in a number of partnered studies, both clinical and pre-clinical, and in studies we are conducting.”
Impel NeuroPharma’s POD™ device is designed to deliver drugs to the upper nasal cavity for improved biodistribution. By delivering therapeutics to the upper nasal cavity, the POD™ device takes advantage of the vascular rich olfactory region for improved bioavailability and has the potential to target the brain via the olfactory and trigeminal nerves. Delivery of therapeutically meaningful levels of drugs may allow for development of more effective drugs and expand the range of treatment options available to patients.
About Impel NeuroPharma
Impel NeuroPharma, Inc. is a Seattle-based company developing intranasal drug treatments for central nervous system (CNS) disorders. Impel NeuroPharma has developed a novel drug delivery platform that administers drug to the deep nasal cavity to improve the biodistribution of many drugs. Impel NeuroPharma’s proprietary POD™ device technology enables entirely new categories of drugs, including biologics, to be administered using a cost-effective, disposable, non-invasive intranasal drug delivery device. To learn more about Impel NeuroPharma please visit our website: www.impelnp.com